Guidance from the release
-
En tant qu'actionnaire et administrateur, je reste optimiste quant à l'avenir de TME Pharma.
Risks mentioned
-
Les capitaux propres au 31 décembre 2025 sont désormais négatifs de 1,6 million d'euros.
-
L'absence de chiffre d'affaires génère des incertitudes financières.
Opportunities identified
-
TME Pharma se concentre sur la conclusion d'accords de licence pour NOX-A12 et NOX-E36.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.